Acurx Pharmaceuticals Announces Advancement of Ibezapolstat to Phase 3 Clinical Trials for C. difficile Infection Treatment

Reuters

2025/06/09

Acurx Pharmaceuticals Announces Advancement of Ibezapolstat to Phase 3 Clinical Trials for C. difficile Infection Treatment

Acurx Pharmaceuticals Inc. has announced the advancement of its lead antibiotic candidate, ibezapolstat, to international pivotal Phase 3 clinical trials for the treatment of C. difficile infection $(CDI.NZ)$. The company has been working in collaboration with Leiden University Medical Center (LUMC) to study the mechanism of action of DNA pol IIIC inhibitors. Results from this collaboration were presented at a scientific conference on May 21 by Dr. Mia Urem from LUMC. These findings provide insight into the structural biology of DNA pol IIIC in complex with inhibitors, which is crucial for developing this new class of antibiotics aimed at treating resistant gram-positive infections. Acurx's Executive Chairman, Bob DeLuccia, emphasized the importance of these data in guiding the design of new compounds to combat antimicrobial resistance. Further details of the presentation are available on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY04694) on June 09, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542389791"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542389791\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542389791?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-09 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542389791","market":"us","top_or_hot":-1,"title":"Acurx Pharmaceuticals Announces Advancement of Ibezapolstat to Phase 3 Clinical Trials for C. difficile Infection Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acurx Pharmaceuticals Announces Advancement of Ibezapolstat to Phase 3 Clinical Trials for C. difficile Infection Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acurx Pharmaceuticals Inc. has announced the advancement of its lead antibiotic candidate, ibezapolstat, to international pivotal Phase 3 clinical trials for the treatment of C. difficile infection <a href=\"https://laohu8.com/S/CDI.NZ\">$(CDI.NZ)$</a>. The company has been working in collaboration with Leiden University Medical Center (LUMC) to study the mechanism of action of DNA pol IIIC inhibitors. Results from this collaboration were presented at a scientific conference on May 21 by Dr. Mia Urem from LUMC. These findings provide insight into the structural biology of DNA pol IIIC in complex with inhibitors, which is crucial for developing this new class of antibiotics aimed at treating resistant gram-positive infections. Acurx's Executive Chairman, Bob DeLuccia, emphasized the importance of these data in guiding the design of new compounds to combat antimicrobial resistance. Further details of the presentation are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY04694) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acurx Pharmaceuticals Announces Advancement of Ibezapolstat to Phase 3 Clinical Trials for C. difficile Infection Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcurx Pharmaceuticals Announces Advancement of Ibezapolstat to Phase 3 Clinical Trials for C. difficile Infection Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-09 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acurx Pharmaceuticals Announces Advancement of Ibezapolstat to Phase 3 Clinical Trials for C. difficile Infection Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acurx Pharmaceuticals Inc. has announced the advancement of its lead antibiotic candidate, ibezapolstat, to international pivotal Phase 3 clinical trials for the treatment of C. difficile infection <a href=\"https://laohu8.com/S/CDI.NZ\">$(CDI.NZ)$</a>. The company has been working in collaboration with Leiden University Medical Center (LUMC) to study the mechanism of action of DNA pol IIIC inhibitors. Results from this collaboration were presented at a scientific conference on May 21 by Dr. Mia Urem from LUMC. These findings provide insight into the structural biology of DNA pol IIIC in complex with inhibitors, which is crucial for developing this new class of antibiotics aimed at treating resistant gram-positive infections. Acurx's Executive Chairman, Bob DeLuccia, emphasized the importance of these data in guiding the design of new compounds to combat antimicrobial resistance. Further details of the presentation are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY04694) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL3JvQsf:1","article_id":"2542389791","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542389791","pubTimestamp":1749468643,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Acurx Pharmaceuticals Inc. has announced the advancement of its lead antibiotic candidate, ibezapolstat, to international pivotal Phase 3 clinical trials for the treatment of C. difficile infection . The company has been working in collaboration with Leiden University Medical Center  to study the mechanism of action of DNA pol IIIC inhibitors. Results from this collaboration were presented at a scientific conference on May 21 by Dr. Mia Urem from LUMC. These findings provide insight into the structural biology of DNA pol IIIC in complex with inhibitors, which is crucial for developing this new class of antibiotics aimed at treating resistant gram-positive infections. Acurx's Executive Chairman, Bob DeLuccia, emphasized the importance of these data in guiding the design of new compounds to combat antimicrobial resistance. Further details of the presentation are available on the company's website.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","ACXP":"Acurx Pharmaceuticals, LLC*","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Acurx Pharmaceuticals宣布Ibezapolstat治疗艰难梭菌感染的3期临床试验进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACXP":0.9},"content_text":"Acurx Pharmaceuticals Announces Advancement of Ibezapolstat to Phase 3 Clinical Trials for C. difficile Infection Treatment\n    \n\n        Acurx Pharmaceuticals Inc. has announced the advancement of its lead antibiotic candidate, ibezapolstat, to international pivotal Phase 3 clinical trials for the treatment of C. difficile infection $(CDI.NZ)$. The company has been working in collaboration with Leiden University Medical Center (LUMC) to study the mechanism of action of DNA pol IIIC inhibitors. Results from this collaboration were presented at a scientific conference on May 21 by Dr. Mia Urem from LUMC. These findings provide insight into the structural biology of DNA pol IIIC in complex with inhibitors, which is crucial for developing this new class of antibiotics aimed at treating resistant gram-positive infections. Acurx's Executive Chairman, Bob DeLuccia, emphasized the importance of these data in guiding the design of new compounds to combat antimicrobial resistance. Further details of the presentation are available on the company's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY04694) on June 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}